John Moriarty

Chief Legal Officer at Mirati Therapeutics

ohn joined Mirati in 2023 as Chief Legal Officer and has more than 25 years of legal and business leadership across leading global biotech companies. Most recently, he was Executive Vice President and Chief Legal Officer at Olema Pharmaceuticals and helped build out the company and lead it through its successful Series C financing and 2020 Initial Public Offering.

Previously he was Executive Vice President and General Counsel for Portola Pharmaceuticals, Inc., where he was responsible for all legal, governance and compliance matters supporting the company’s products, its corporate strategy, and the build-out of its operations in the United States and Europe, which culminated in Portola’s acquisition by Alexion Pharmaceuticals, Inc. in July 2020. Prior to Portola, John was General Counsel of Alexion for more than five years during a period of tremendous growth and value creation. He was responsible for overseeing all global legal matters spanning 50 countries, as well as managing Alexion’s Global Government Affairs and Global Corporate Communications teams.

Earlier in his career, John was General Counsel at Elan Corporation plc and a senior lawyer at Amgen. John also worked as in the healthcare practice of a national law firm and was a healthcare fraud prosecutor in the U.S. Attorney’s Office and in the Virginia Attorney General’s Office. John earned his undergraduate degree from the University of Virginia and his law degree from the University of Georgia School of Law cum laude. From 2015 through 2022 John served on the Board of Trustees for the American Kidney Fund and chaired the Audit and Compliance Committee.


Previous companies

Olema Oncology logo
Portola Pharmaceuticals logo
Amgen logo
Alexion Pharmaceuticals logo
Epstein Becker & Green, P.C. logo


  • Chief Legal Officer

    January, 2023 - present